Sanfe Risk Report

⚖️ Legal & Regulatory

Sanfe has faced challenges related to false claims about product approvals, which may indicate issues with legal compliance. The repeated accusations of falsely claiming regulatory approvals are significant risks. Ensuring transparent communication and robust compliance measures is crucial for Sanfe to maintain its credibility and avoid regulatory penalties.

• On 🗓 April 7, 2019, Sanfe was accused of falsely claiming FDA approval and AYUSH Ministry certification for a period pain relief roll-on.
• A show cause notice was issued by IIT Delhi on 🗓 April 9, 2019, due to the same approval claim issues.
• Further accusations of false approval claims arose on 🗓 September 11, 2019.

📜 Innovation & R&D

Sanfe is focusing on innovation to enhance their product offerings in feminine hygiene and skincare. Their developments, such as the GlycoClear technology, show a commitment to advancing their product line and maintaining competitive advantage. These innovations can serve as opportunities to expand market share and attract a broader customer base.

• On 🗓 February 9, 2024, Sanfe developed GlycoClear technology to redefine body care standards.
• On 🗓 February 10, 2024, Sanfe introduced GlycoClear technology in feminine skincare, setting a new standard according to an announcement on Indian Retailer.

🏅 Awards & Recognition

No entries are available for this category.

Sanfe's proactive approach in product innovation and handling past challenges in regulatory compliance indicates a company that is learning and evolving. By continuing to focus on transparent practices and leveraging their R&D advancements, Sanfe is positioned to strengthen its market position in the wellness and hygiene sector. However, ensuring consistent compliance with legal standards remains essential to minimize potential risks.